Oncolytic viruses: Do they have a role in anti-cancer therapy?

Clinical Medicine: Oncology

Volumn 2, Issue , 2008, Pages 83-96

  Prestwich, Robin J ^a   Errington, Fiona ^a   Harrington, Kevin J ^b,c   Pandha, Hardev S ^d   Selby, Peter ^a   Melcher, Alan ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Administration; Anti tumour immunity; Oncolytic virus; Safety; Tumor selectivity; Virus delivery

Indexed keywords

EID: 84885643372     PISSN: None     EISSN: 11779314     Source Type: Journal    
DOI: 10.4137/cmo.s416     Document Type: Review

References (116)

1. Advani, S.J., Mezhir, J.J, Roizman, B. and Weichselbaum, R.R. 2006. ReVOLT: radiation-enhanced viral oncolytic therapy. International Journal of Radiation Oncology Biology Physics, 66:637.
2. Advani, S.J., Sibley, G.S., Song, P.Y., Hallahan, D.E., Kataoka, Y., Roizman, B. and Weichselbaum, R.R. 1998. Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors. Gene. Ther., 5:160-5.
3. Aghi, M. and Martuza, R.L. 2005. Oncolytic viral therapies-the clinical experience. Oncogene, 24:7802-16.
4. Ahmed, A., Jevremovic, D., Suzuki, K., Kottke, T., Thompson., J., Emery, S., Harrington, K., Bateman, A. and Vile, R. 2003. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene. Ther., 10:1663-71.
5. Alain, T., Kim, T.S., Lun, X., Liacini, A., Schiff, L.A., Senger, D.L. and Forsyth, P.A. 2007. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol. Ther., 15:1512-21.
6. Alexopoulou, L., Holt, A.C., Medzhitov, R. and Flavell, R.A. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature, 413:732-8.
7. Banchereau, J., Schuler-Thurner, B., Palucka, A.K. and Schuler, G. 2001. Dendritic cells as vectors for therapy. Cell, 106:271-4.
8. Bangari, D.S. and Mittal, S.K. 2006. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther., 6:215-26.
9. Barber, G.N. 2005. VSV-tumor selective replication and protein translation. Oncogene, 24:7710-9.
10. Bateman, A., Bullough, F., Murphy, S., Emiliusen, L., Lavillette, D., Cosset, F.L., Cattaneo, R., Russell, S.J. and Vile, R.G. 2000. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res., 60:1492-7.
11. Baxter, L.T., Zhu, H., Mackensen, D.G. and Jain, R.K. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res., 54:1517-28.
12. Bischoff, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A. and Mccormick, F. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science, 274:373-6.
13. Blank, S.V., Rubin, S.C., Coukos, G., Amin, K.M., Albelda, S.M. and Molnar-Kimber, K.L. 2002. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by lowdose radiation. Hum. Gene. Ther., 13:627-39.
14. Blomer, U., Gruh, I., Witschel, H., Haverich, A. and Martin, U. 2005. Shuttle of lentiviral vectors via transplanted cells in vivo. Gene. Ther., 12:67-74.
15. Bluming, A.Z. and Ziegler, J.L. 1971. Regression of Burkitt's lymphoma in association with measles infection. Lancet, 2:105-6.
16. Brown, S.M., Harland, J., Maclean, A.R., Podlech, J. and Clements, J.B. 1994. Cell. type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J. Gen Virol., 75 (Pt 9):2367-77.
17. Chen, Y., Yu, D.C., Charlton, D. and Henderson, D.R. 2000. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum. Gene. Ther., 11:1553-67.
18. Chernajovsky, Y., Layward, L. and Lemoine, N. 2006. Fighting cancer with oncolytic viruses. BMJ., 332:170-2.
19. Coffey, M.C., Strong, J.E., Forsyth, P.A. and Lee, P.W. 1998. Reovirus therapy of tumors with activated Ras pathway. Science, 282:1332-4.
20. Cole, C., Qiao, J., Kottke, T., Diaz, R.M., Ahmed, A., Sanchez-Perez, L., Brunn, G., Thompson, J., Chester, J. and Vile, R.G. 2005. Tumortargeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat. Med., 11:1073.
21. Croyle, M.A., Chirmule, N., Zhang, Y. and Wilson, J.M. 2002. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene. Ther., 13:1887-900.
22. De Haro, C., Mendez, R. and Santoyo, J. 1996. The eIF-2alpha kinases and the control of protein synthesis. Faseb. J., 10:1378-87.
23. Depace, N. 1912. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senza cura chirurgica. Ginecologia, 9:82-88.
24. Diaz, R.M., Galivo, F., Kottke, T., Wongthida, P., Qiao, J., Thompson, J., Valdes, M., Barber, G. and Vile, R.G. 2007. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res., 67:2840-8.
25. Dolan, A., Mckie, E., Maclean, A.R. and Mcgeoch, D.J. 1992. Status of the ICP34.5 gene in herpes simplex virus type 1 strain 17. J. Gen. Virol., 73 (Pt 4):971-3.
26. Fishelson, Z., Donin, N., Zell, S., Schultz, S. and Kirschfink, M. 2003. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol. Immunol., 40:109-23.
27. Fisher, K. 2006. Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr. Opin. Mol. Ther., 8:301-13.
28. Fulci, G., Breymann, L., Gianni, D., Kurozomi, K., Rhee, S.S., Yu, J., Kaur, B., Louis, D.N., Weissleder, R., Caligiuri, M.A. and Chiocca, E.A. 2006. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc. Natl. Acad. Sci. U.S.A., 103:12873-8.
29. Gallucci, S. and Matzinger, P. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol., 13:114-9.
30. Geijtenbeek, T.B., Kwon, D.S., Torensma, R., Van Vliet, S.J., Van Duijnhoven, G.C., Middel, J., Cornelissen, I.L., Nottet, H.S., Kewalramani, V.N., Littman, D.R., Figdor, C.G. and Van Kooyk, Y. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances transinfection of T cells. Cell, 100:587-97.
31. Greiner, S., Humrich, J.Y., Thuman, P., Sauter, B., Schuler, G. and Jenne, L. 2006. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin. Exp. Immunol., 146:344-53.
32. Grote, D., Russell, S.J., Cornu, T.I., Cattaneo, R., Vile, R., Poland, G.A. and Fielding, A.K. 2001. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood, 97:3746-54.
33. Gunzburg, W.H. 2005. Oncolytic replicating virus therapy: is the time right? Curr. Opin. Mol. Ther., 7:291-2.
34. Hansen, R.M. and Libnoch, J.A. 1978. Remission of chronic lymphocytic leukemia after smallpox vaccination. Arch. Intern. Med., 138:1137-8.
35. Harris, D., Vidal, L., Melcher, A., Newbold, K., Karavisilis, V., Ararwal, R., Anthony, A., Coffey, M., Mettinger, K., Kirkpatrick, M., Lee, J., Twigger, K., White, C., Pandha, H., De Bono, J. and Harrington, K. 2007. A phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild type reovirus (Reolysin) in combination with radiation in patients with advanced malignancies (Abst). Oncolytics Biotech Inc. Accessed 21 November 2007. URL. http://www.oncolytics.biotech.com
36. Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S.M. and Rampling, R. 2004. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther., 11:1648-58.
37. Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D.D. and Kirn, D.H. 1997. ONYX-015, an E1B. gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3:639-45.
38. Hersey, P., Coates, A.S., Mccarthy, W.H., Thompson, J.F., Sillar, R.W., Mcleod, R., Gill, P.G., Coventry, B.J., Mcmullen, A., Dillon, H. and Simes, R.J. 2002. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol., 20:4181-90.
39. Hersey, P., Edwards, A., Coates, A., Shaw, H., Mccarthy, W. and Milton, G. 1987. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol. Immunother., 25:257-65.
40. Hotte, S.J., Lorence, R.M., Hirte, H.W., Polawski, S.R., Bamat, M.K., O'neil, J.D., Roberts, M.S., Groene, W.S. and Major, P.P. 2007. An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res., 13:977-85.
41. Hu, J.C., Coffin, R.S., Davis, C.J., Graham, N.J., Groves, N., Guest, P.J., Harrington, K.J., James, N.D., Love, C.A., Mcneish, I., Medley, L.C., Michael, A., Nutting, C.M., Pandha, H.S., Shorrock, C.A., Simpson, J., Steiner, J., Steven, N.M., Wright, D. and Coombes, R.C. 2006. A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res., 12:6737-47.
42. Iankov, I.D., Blechacz, B., Liu, C., Schmeckpeper, J.D., Tarara, J.E., Federspiel, M.J., Caplice, N. and Russell, S.J. 2007. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol. Ther., 15:114-22.
43. Jain, R.K. 1987. Transport of molecules across tumor vasculature. Cancer Metastasis. Rev., 6:559-93.
44. Jenne, L., Arrighi, J.F., Jonuleit, H., Saurat, J.H. and Hauser, C. 2000. Dendritic cells containing apoptotic melanoma cells prime human CD8llT cells for efficient tumor cell lysis. Cancer Res., 60:4446-52.
45. Kelly, E. and Russell, S.J. 2007. History of oncolytic viruses: genesis to genetic engineering. Mol. Ther., 15:651-9.
46. Kim, J.H., Lee, Y.S., Kim, H., Huang, J.H., Yoon, A.R. and Yun, C.O. 2006. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J. Natl. Cancer Inst., 98:1482-93.
47. Kirn, D. 2001. Clinical research results with dl1520 (Onyx-015), a replicationselective adenovirus for the treatment of cancer: what have we learned? Gene Ther., 8:89-98.
48. Ko, D., Hawkins, L. and Yu, D.C. 2005. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene, 24:7763-74.
49. Kuriyama, N., Kuriyama, H., Julin, C.M., Lamborn, K. and Israel, M.A. 2000. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy. Hum. Gene Ther., 11:2219-30.
50. Li, H., Dutuor, A., Fu, X. and Zhang, X. 2007a. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. J. Gene. Med., 9:161-9.
51. Li, H., Dutuor, A., Tao, L., Fu, X. and Zhang, X. 2007b. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin. Cancer Res., 13:316-22.
52. Li, Z.Y., Ni, S., Yang, X., Kiviat, N. and Lieber, A. 2004. Xenograft models for liver metastasis: Relationship between tumor morphology and adenovirus vector transduction. Mol. Ther., 9:650-7.
53. Liu, T.C. and KIRN, D. 2007. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res., 67:429-32.
54. Lorence, R.M., Pecora, A.L., Major, P.P., Hotte, S.J., Laurie, S.A., Roberts, M.S., Groene, W.S. and Bamat, M.K. 2003. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr. Opin. Mol. Ther., 5:618-24.
55. Lyons, M., Onion, D., Green, N.K., Aslan, K., Rajaratnam, R., Bazan- Peregrino, M., Phipps, S., Hale, S., Mautner, V., Seymour, L.W. and Fisher, K.D. 2006. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther., 14:118-28.
56. Mackie, R.M., Stewart, B. and Brown, S.M. 2001. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet, 357:525-6.
57. Maisner, A., Mrkic, B., Herrler, G., Moll, M., Billeter, M.A., Cattaneo, R. and Klenk, H.D. 2000. Recombinant measles virus requiring an exogenous protease for activation of infectivity. J. Gen Virol., 81:441-9.
58. Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D. and Lee, P.W. 2007. Ras Transformation Mediates Reovirus Oncolysis by Enhancing Virus Uncoating, Particle Infectivity, and Apoptosis-dependent Release. Mol. Ther., 15:1522-30.
59. Martuza, R.L., Malick, A., Markert, J.M., Ruffner, K.L. and Coen, D.M. 1991. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science, 252:854-6.
60. Mastrangelo, M.J. and Lattime, E.C. 2002. Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors. Cancer Gene Ther., 9:1013-21.
61. Mastrangelo, M.J., Maguire, H.C.,Jr., Eisenlohr, L.C., Laughlin, C.E., Monken, C.E., Mccue, P.A., Kovatich, A.J. and Lattime, E.C. 1999. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., 6:409-22.
62. Matthews, C., Jenkins, G., Hilfinger, J. and Davidson, B. 1999. Poly-L-lysine improves gene transfer with adenovirus formulated in PLGA microspheres. Gene Ther., 6:1558-64.
63. Matzinger, P. 1994. Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12:991-1045.
64. Matzinger, P. 1998. An innate sense of danger. Semin. Immunol., 10:399-415.
65. Mccormick, F. 2001. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer, 1:130-41.
66. Mccormick, F. 2003. Cancer-specific viruses and the development of ONYX- 015. Cancer Biol. Ther., 2:S157-60.
67. Mckee, T.D., Grandi, P., Mok, W., Alexandrakis, G., Insin, N., Zimmer, J.P., Bawendi, M.G., Boucher, Y., Breakefield, X.O. and Jain, R.K. 2006. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res., 66:2509-13.
68. Medina-Kauwe, L.K. 2003. Endocytosis of adenovirus and adenovirus capsid proteins. Adv. Drug Deliv. Rev., 55:1485-96.
69. Mestas, J. and Hughes, C.C. 2004. Of mice and not men: differences between mouse and human immunology. J. Immunol., 172:2731-8.
70. Minchinton., A.I. and Tannock, I.F. 2006. Drug penetration in solid tumours. Nat. Rev. Cancer, 6:583-92.
71. Moehler, M.H., Zeidler, M., Wilsberg, V., Cornelis, J.J., Woelfel, T., Rommelaere, J., Galle, P.R. and Heike, M. 2005. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene. Ther., 16:996-1005.
72. Mohamed, M.M. and Sloane, B.F. 2006. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer, 6:764-75.
73. Molema, G., De Leij, L.F. and Meijer, D.K. 1997. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res., 14:2-10.
74. Nakamura, T., Peng, K.W., Harvey, M., Greiner, S., Lorimer, I.A., James, C.D. and Russell, S.J. 2005. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol., 23:209-14.
75. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., Mccarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S. and Kirn, D. 2000. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res, 60:6359-66.
76. O'riordan, C.R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S.C., Smith, A.E. and Francis, G.E. 1999. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther., 10:1349-58.
77. O'shea, C.C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., Shen, Y., Habets, G., Ginzinger, D. and Mccormick, F. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell., 6:611-23.
78. Ong, H.T., Hasegawa, K., Dietz, A.B., Russell, S.J. and Peng, K.W. 2007. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther., 14:324-33.
79. Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R. and Brown, M. 2002. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene. Ther., 9:398-406.
80. Parato, K.A., Senger, D., Forsyth, P.A.J. and Bell, J.C. 2005. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer, 5:965-76.
81. Pecora, A.L., Rizvi, N., Cohen, G.I., Meropol, N.J., Sterman, D., Marshall, J.L., Goldberg, S., Gross, P., O'neil, J.D., Groene, W.S., Roberts, M.S., Rabin, H., Bamat, M.K. and Lorence, R.M. 2002. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol., 20:2251-66.
82. Pizzato, M., Marlow, S.A., Blair, E.D. and Takeuchi, Y. 1999. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J. Virol., 73:8599-611.
83. Pollara, G., Kwan, A., Newton, P.J., Handley, M.E., Chain, B.M. and Katz, D.R. 2005. Dendritic cells in viral pathogenesis: protective or defective? International Journal of Experimental Pathology, 86:187-204.
84. Power, A.T., Wang, J., Falls, T.J., Paterson, J.M., Parato, K.A., Lichty, B.D., Stojdl, D.F., Forsyth, P.A., Atkins, H. and Bell, J.C. 2007. Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity. Mol. Ther., 15:123-30.
85. Rampling, R., Cruickshank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., Maclean, A., Harland, J., Mckie, E., Mabbs, R. and Brown, M. 2000. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene. Ther., 7:859-66.
86. Raykov, Z., Grekova, S., Galabov, A.S., Balboni, G., Koch, U., Aprahamian., M. and Rommelaere, J. 2007. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol. Rep., 17:1493-9.
87. Roberts, M.S., Lorence, R.M., Groene, W.S. and Bamat, M.K. 2006. Naturally oncolytic viruses. Curr. Opin. Mol. Ther., 8:314-21.
88. Rogulski, K.R., Wing, M.S., Paielli, D.L., Gilbert, J.D., Kim, J.H. and Freytag, S.O. 2000. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum. Gene Ther., 11:67-76.
89. Russell, S.J. 2002. RNA viruses as virotherapy agents. Cancer Gene Ther., 9:961-6.
90. Sauthoff, H., Hu, J., Maca, C., Goldman, M., Heitner, S., Yee, H., Pipiya, T., Rom, W.N. and Hay, J.G. 2003. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther., 14:425-33.
91. Schirrmacher, V. 2005. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother., 54:587-98.
92. Schirrmacher, V., Ahlert, T., Probstle, T., Steiner, H.H., Herold-Mende, C., Gerhards, R., Hagmuller, E. and Steiner, H.H. 1998. Immunization with virus-modified tumor cells. Semin. Oncol., 25:677-96.
93. Schlag, P., Manasterski, M., Gerneth, T., Hohenberger, P., Dueck, M., Herfarth, C., Liebrich, W. and Schirrmacher, V. 1992. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol. Immunother., 35:325-30.
94. Shayakhmetov, D.M., Li, Z.Y., Ni, S. and Lieber, A. 2002. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res., 62:1063-8.
95. Shmulevitz, M., Marcato, P. and Lee, P.W. 2005. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene, 24:7720-8.
96. Smakman., N., Van Der Bilt, J.D., Van Den Wollenberg, D.J., Hoeben. R.C., Borel Rinkes, I.H. and Kranenburg, O. 2006. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther., 13:815-8.
97. Spicer, J., Vidal, L., Pandha, H., Yap, T.A., Digue, L., Coffey, M., Thompson, B., Kaye, S.B., Harrington, K.J. and De Bono, J. 2007. Final results of a phase I study of oncolytic reovirus administered intravenously to patients with advanced cancer (Abst). Oncolytics Biotech Inc. Accessed 21 November 2007. URL. http://www. oncolytics.biotech.com
98. Stanziale, S.F., Petrowsky, H., Joe, J.K., Roberts, G.D., Zager, J.S., Gusani, N.J., Ben-Porat, L., Gonen, M. and Fong, Y. 2002. Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery, 132:353-9.
99. Steiner, H.H., Bonsanto, M.M., Beckhove, P., Brysch, M., Geletneky, K., Ahmadi, R., Schuele-Freyer, R., Kremer, P., Ranaie, G., Matejic, D., Bauer, H., Kiessling, M., Kunze, S., Schirrmacher, V. and Herold- Mende, C. 2004. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J. Clin. Oncol., 22:4272-81.
100. Stevenson, M., Hale, A.B., Hale, S.J., Green, N.K., Black, G., Fisher, K.D., Ulbrich, K., Fabra, A. and Seymour, L.W. 2007. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther., 14:335-45.
101. Stoeckel, J. and Hay, J.G. 2006. Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr. Opin. Mol. Ther., 8:249-60.
102. Stojdl, D.F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N. and Bell, J.C. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6:821-5.
103. Stoler, D.L., Chen, N., Basik, M., Kahlenberg, M.S., Rodriguez-Bigas, M.A., Petrelli, N.J. and Anderson, G.R. 1999. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl. Acad. Sci. U.S.A., 96:15121-6.
104. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P. and Lee, P.W. 1998. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. Embo. J., 17:3351-62.
105. Thorne, S.H., Negrin, R.S. and Contag, C.H. 2006. Synergistic antitumor effects of immune cell-viral biotherapy. Science, 311:1780-4.
106. Toda, M., Rabkin, S.D., Kojima, H. and Martuza, R.L. 1999. Herpes simplex virus as an in situ cancer vaccine for the induction of specific antitumor immunity. Hum. Gene Ther., 10:385-93.
107. Tsai, V., Johnson, D.E., Rahman, A., Wen, S.F., Laface, D., Philopena, J., Nery, J., Zepeda, M., Maneval, D.C., Demers, G.W. and Ralston, R. 2004. Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin. Cancer Res., 10:7199-206.
108. Tylerkl, 2001. Mammalian reoviruses. In Lippencott Fields Virology, Williams and Wilkens: Philidelphia.
109. Vaha-Koskela, M.J., Heikkila, J.E. and Hinkkanen, A.E. 2007. Oncolytic viruses in cancer therapy. Cancer Lett., 254:178-216.
110. Vasey, P.A., Shulman, L.N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn., D.H., O'neill, V., Siddiqui, N., Seiden, M.V. and Kaye, S.B. 2002. Phase I trial of intraperitoneal injection of the E1B-55-kd-genedeleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol., 20:1562-9.
111. Worgall, S., Wolff, G., Falck-Pedersen, E. and Crystal, R.G. 1997. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther., 8:37-44.
112. Xia, Z.J., Chang, J.H., Zhang, L., Jiang, W.Q., Guan, Z.Z., Liu, J.W., Zhang, Y., Hu, X.H., Wu, G.H., Wang, H.Q., Chen, Z.C., Chen, J.C., Zhou, Q.H., Lu, J.W., Fan, Q.X., Huang, J.J. and Zheng, X. 2004. [Phase III randomized clinical trial of intratumoral injection of E1B. gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai. Zheng., 23:1666-70.
113. Ye, X., Jerebtsova, M. and Ray, P.E. 2000. Liver bypass significantly increases the transduction efficiency of recombinant adenoviral vectors in the lung, intestine, and kidney. Hum. Gene Ther., 11:621-7.
114. Zajac, P., Oertli, D., Marti, W., Adamina, M., Bolli, M., Guller., U., Noppen, C., Padovan, E., Schultz-Thater, E., Heberer, M. and Spagnoli, G. 2003. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum. Gene Ther., 14:1497-510.
115. Zeh, H.J. and Bartlett, D.L. 2002. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther., 9:1001-12.
116. Zeng, J., Fournier, P. and Schirrmacher, V. 2002. Induction of interferonalpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology, 297:19-30.